Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BHV3500-203: Phase 2/3: Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of Zavegepant (BHV-3500) Intranasal (IN) for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen

NCT04346615 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT04346615
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04346615 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BHV3500-203: Phase 2/3: Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of Zavegepant (BHV-3500) Intranasal (IN) for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen
Lead sponsor
Pfizer
Phase
Phase 2/3
Overall status
Terminated
Start date
April 25, 2020
Completion date
April 29, 2022
Enrollment
47 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 infection